Chia Tai Tianqing: CA111 Injection Receives Clinical Trial Approval Letter

Chia Tai Bio announced that CA111 injection developed by its subsidiary, Chen'an Biotechnology, has obtained the approval notice for drug clinical trials from the National Medical Products Administration, allowing clinical trials to be conducted in adult overweight or obese patients. CA111 injection is a dual agonist of glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor. Compared to similar drugs targeting a single point, the dual agonist can effectively reduce the side effects of administration through synergistic complementation. Currently, only lixisenatide injection has been approved for marketing domestically, with no other similar domestic products approved for marketing.